Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation

BACKGROUND: Prospectively designed studies assessing the exposure‐response profile of vedolizumab are lacking. Observational exposure‐response data for vedolizumab are limited and have not been adjusted for potential confounding factors, particularly those that may affect vedolizumab clearance. AIMS...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Aliment Pharmacol Ther
Autors principals: Osterman, Mark T., Rosario, Maria, Lasch, Karen, Barocas, Morris, Wilbur, Jayson D., Dirks, Nathanael L., Gastonguay, Marc R.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
Dose Optimisation of Vedolizumab in Ulcerative Colitis
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6590294/
https://ncbi.nlm.nih.gov/pubmed/30663076
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.15113
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars